← All trials
NCT07032714
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 16, 2025
- Primary completion
- Jul 1, 2027
- Completion date
- Jul 1, 2028
- First posted
- Jun 24, 2025
- Last posted
- Jun 26, 2025
- Enrollment
- 25
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversitySponsor investigator
- CelgeneCollaborator
- Harvard UniversityOfficial
- Johnson and JohnsonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.